ABT — Abbott Laboratories

Is ABT overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Medical Devices

Overbought As of August 19, 2026

Abbott Laboratories (ABT) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Medical Devices) last closed at $114.46. The rating moved from Neutral to Overbought on July 19, 2026.

See all overbought Healthcare stocks →

AI analysis

Abbott Laboratories (ABT) combines a diversified product portfolio with consistent cash generation and a strong market position in diabetes monitoring, diagnostics, and cardiovascular devices. Near-term market conditions are calm, enabling company-specific fundamentals and earnings commentary to guide performance. Growth catalysts include continued adoption of CGM, durable demand for diagnostics and procedure-related consumables, and margin expansion from recurring-revenue mix. Key downside risks are reimbursement dynamics, regulatory events, supply-chain pressures, and competitive intensity. Overall, the company is positioned for steady organic growth with a favorable balance-sheet profile that supports cash returns and measured M&A or R&D investment.

Key factors

  • Diversified medical-device and diagnostics franchise with leading positions in diabetes care (FreeStyle Libre), point-of-care testing, cardiovascular devices, and established nutrition business, providing stable revenue mix and resilience to single-end-market shocks.
  • Strong financial profile: consistent free cash flow generation, investment-grade balance sheet, and a history of shareholder returns via dividends and buybacks that support valuation stability.
  • Ongoing demand in diagnostics and image-guided procedures that benefits Abbott’s instrument and consumables businesses; secular growth in chronic disease monitoring (CGM) underpins medium-term revenue growth.
  • Product pipeline and incremental software/algorithm enhancements on existing platforms can expand recurring consumables and services revenue and improve gross margins.
  • Favorable sector themes around diagnostics & screening and synthetic-biology/CRO strength indirectly support parts of Abbott’s diagnostics and lab-supply exposure.
  • Limited near-term macro/policy noise in the market window reduces short-term volatility and allows fundamentals and earnings commentary to drive price action.

Risks

  • Reimbursement pressure or adverse changes to payer policies that could reduce pricing or utilization for devices and diagnostic tests.
  • Competitive pressure from established device makers and emerging entrants (e.g., Dexcom in CGM, large diversified medtech firms) that could erode share or pricing power.
  • Regulatory and recall risk for devices and diagnostics (FDA actions, 510(k) or PMA outcomes) that could delay launches or increase compliance costs.
  • Supply-chain disruptions or component inflation that compress margins or limit growth in higher-demand product lines.
  • Execution risk on commercialization of upgrades/software and on converting installed base to higher-margin recurring revenue.
  • Macroeconomic slowdown that reduces elective procedure volumes and corporate capital spending, impacting device sales.

Latest MarketMoodz coverage

See today's live rating, score and targets

Members see the live hourly rating for ABT — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.